Ademi LLP Investigates Claims of Securities Fraud against Athira Pharma, Inc.
MILWAUKEE, June 21, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Athira (NASDAQ: ATHA). The investigation results from inaccurate statements Athira may have made regarding its business operations and prospects.
Click here to learn more about the investigation: https://www.ademilaw.com/case/athira-pharma-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
The investigation focuses on whether Athira properly disclosed the facts underlying doctoral research conducted by Leen Kawas, PhD, President and Chief Executive Officer of Athira, at Washington State University. Athira was founded by Kawas and others based on research conducted at Washington State and subsequent peer review has suggested that images in papers authored by Kawas could have been manipulated.
If you wish to obtain additional information or have information about this investigation, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, https://www.ademilaw.com/case/athira-pharma-inc.
We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Ademi LLP
Guri Ademi
3620 East Layton Ave.
Cudahy, WI 53110
Toll Free: (866) 264-3995
Fax: (414) 482-8001
www.ademilaw.com
View original content:http://www.prnewswire.com/news-releases/ademi-llp-investigates-claims-of-securities-fraud-against-athira-pharma-inc-301316145.html
SOURCE Ademi LLP
